What is Lifeward?
Formerly known as ReWalk Robotics, Lifeward operates at the intersection of biomechanics and healthcare technology. The company is dedicated to developing groundbreaking solutions for individuals living with physical limitations or disabilities. Its comprehensive product ecosystem includes the ReWalk Exoskeleton, ReStore Exo-Suit, MYOLYN FES bikes, and the recently acquired AlterG Anti-Gravity systems. By focusing on high-impact mobility solutions, Lifeward has established itself as a pivotal player in the rehabilitation market, consistently pushing the boundaries of what is possible in patient care and functional recovery.
How much funding has Lifeward raised?
Lifeward has raised a total of $31.2M across 2 funding rounds:
Stock/Share Issuance
$20M
Unspecified
$11.2M
Stock/Share Issuance (2026): $20M, investors not publicly disclosed
Unspecified (2026): $11.2M, investors not publicly disclosed
Key Investors in Lifeward
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lifeward?
With this major enterprise-level funding, Lifeward is positioned to scale its operational footprint and enhance its research and development capabilities. The strategic focus will likely shift toward the global commercialization of its integrated portfolio, aiming to elevate the standard of care for patients worldwide. As the company transitions into this next phase of growth, investors will be monitoring its ability to leverage these resources to drive market penetration and achieve long-term sustainability in the competitive medical robotics landscape. The company's commitment to innovation suggests a future roadmap centered on expanding the accessibility of its assistive technologies to a wider demographic of users.
See full Lifeward company page
